A Phase II Study of Axitinib in Advanced Carcinoid Tumors: Preliminary Results Abstract #1179

Introduction: NETs are highly vascularized neoplasms overexpressing VEGF as well as VEGFR. Axitinib is a TKI with selective picomolar potency against VEGFR-1, -2 and -3
Aim(s): To evaluate the safety and efficacy of axitinib in patients with advanced carcinoid tumors
Materials and methods: We performed a phase II trial of axitinib 5 mg BID in patients with advanced low to intermediate grade carcinoid tumors. Prior antiangiogenic therapy with a dedicated VEGF pathway inhibitor was not permitted. The primary endpoints were PFS and 1-year PFS rate
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Mauro Cives

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result